356 related articles for article (PubMed ID: 22683884)
1. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
[TBL] [Abstract][Full Text] [Related]
2. Analysis of sequences of hepatitis C virus NS5A genotype 1 in HIV-coinfected patients with a null response to nitazoxanide or peg-interferon plus ribavirin.
Sede M; Laufer N; Ojeda D; Gun A; Cahn P; Quarleri J
Arch Virol; 2013 Sep; 158(9):1907-15. PubMed ID: 23553458
[TBL] [Abstract][Full Text] [Related]
3. Analysis of the PKR-eIF2alpha phosphorylation homology domain (PePHD) of hepatitis C virus genotype 1 in HIV-coinfected patients by ultra-deep pyrosequencing and its relationship to responses to pegylated interferon-ribavirin treatment.
Bolcic F; Sede M; Moretti F; Westergaard G; Vazquez M; Laufer N; Quarleri J
Arch Virol; 2012 Apr; 157(4):703-11. PubMed ID: 22270759
[TBL] [Abstract][Full Text] [Related]
4. Mutations in E2-PePHD, NS5A-PKRBD, NS5A-ISDR, and NS5A-V3 of hepatitis C virus genotype 1 and their relationships to pegylated interferon-ribavirin treatment responses.
Muñoz de Rueda P; Casado J; Patón R; Quintero D; Palacios A; Gila A; Quiles R; León J; Ruiz-Extremera A; Salmerón J
J Virol; 2008 Jul; 82(13):6644-53. PubMed ID: 18448540
[TBL] [Abstract][Full Text] [Related]
5. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
[TBL] [Abstract][Full Text] [Related]
6. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
[TBL] [Abstract][Full Text] [Related]
7. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection.
Murphy MD; Rosen HR; Marousek GI; Chou S
Dig Dis Sci; 2002 Jun; 47(6):1195-205. PubMed ID: 12064791
[TBL] [Abstract][Full Text] [Related]
8. Mutations in the E2 and NS5A regions in patients infected with hepatitis C virus genotype 1a and their correlation with response to treatment.
Yahoo N; Sabahi F; Shahzamani K; Malboobi MA; Jabbari H; Sharifi H; Mousavi-Fard SH; Merat S
J Med Virol; 2011 Aug; 83(8):1332-7. PubMed ID: 21678437
[TBL] [Abstract][Full Text] [Related]
9. Genetic variability of hepatitis C virus in chronically infected patients with viral breakthrough during interferon-ribavirin therapy.
Vuillermoz I; Khattab E; Sablon E; Ottevaere I; Durantel D; Vieux C; Trepo C; Zoulim F
J Med Virol; 2004 Sep; 74(1):41-53. PubMed ID: 15258967
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C virus NS5A region mutation in chronic hepatitis C genotype 1 patients who are non-responders to two or more treatments and its relationship with response to a new treatment.
Muñoz de Rueda P; Fuentes Rodríguez JM; Quiles Pérez R; Gila Medina A; Martín Álvarez AB; Casado Ruíz J; Ruíz Extremera A; Salmerón J
World J Gastroenterol; 2017 Jul; 23(25):4538-4547. PubMed ID: 28740342
[TBL] [Abstract][Full Text] [Related]
11. Sequence heterogeneity of NS5A and core proteins of hepatitis C virus and virological responses to pegylated-interferon/ribavirin combination therapy.
El-Shamy A; Shoji I; Saito T; Watanabe H; Ide YH; Deng L; Kawata S; Hotta H
Microbiol Immunol; 2011 Jun; 55(6):418-26. PubMed ID: 21371092
[TBL] [Abstract][Full Text] [Related]
12. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
[TBL] [Abstract][Full Text] [Related]
13. Impact of NS5A sequences of Hepatitis C virus genotype 1a on early viral kinetics during treatment with peginterferon- alpha 2a plus ribavirin.
Dal Pero F; Tang KH; Gerotto M; Bortoletto G; Paulon E; Herrmann E; Zeuzem S; Alberti A; Naoumov NV
J Infect Dis; 2007 Oct; 196(7):998-1005. PubMed ID: 17763320
[TBL] [Abstract][Full Text] [Related]
14. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
[TBL] [Abstract][Full Text] [Related]
15. Does sequencing the PKRBD of hepatitis C virus NS5A predict therapeutic response to combination therapy in an Australian population?
Macquillan GC; Niu X; Speers D; English S; Garas G; Harnett GB; Reed WD; Allan JE; Jeffrey GP
J Gastroenterol Hepatol; 2004 May; 19(5):551-7. PubMed ID: 15086599
[TBL] [Abstract][Full Text] [Related]
16. Correlation between mutations in the core and NS5A genes of hepatitis C virus genotypes 1a, 1b, 3a, 3b, 6f and the response to pegylated interferon and ribavirin combination therapy.
Kumthip K; Pantip C; Chusri P; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
J Viral Hepat; 2011 Apr; 18(4):e117-25. PubMed ID: 20955493
[TBL] [Abstract][Full Text] [Related]
17. NS5A(ISDR-V3) region genetic variability of Tunisian HCV-1b strains: Correlation with the response to the combined interferon/ribavirin therapy.
Bouzgarrou N; Hassen E; Mahfoudh W; Gabbouj S; Schvoerer E; Ben Yahia A; Ben Mami N; Triki H; Chouchane L
J Med Virol; 2009 Dec; 81(12):2021-8. PubMed ID: 19856481
[TBL] [Abstract][Full Text] [Related]
18. Mutations in two PKR-binding domains in chronic hepatitis C of genotype 3a and correlation with viral loads and interferon responsiveness.
Yokozaki S; Katano Y; Hayashi K; Ishigami M; Itoh A; Hirooka Y; Nakano I; Goto H
J Med Virol; 2011 Oct; 83(10):1727-32. PubMed ID: 21837788
[TBL] [Abstract][Full Text] [Related]
19. Quasispecies heterogeneity of the carboxy-terminal part of the E2 gene including the PePHD and sensitivity of hepatitis C virus 1b isolates to antiviral therapy.
Sarrazin C; Bruckner M; Herrmann E; Rüster B; Bruch K; Roth WK; Zeuzem S
Virology; 2001 Oct; 289(1):150-63. PubMed ID: 11601926
[TBL] [Abstract][Full Text] [Related]
20. Genetic Variability of Hepatitis C Virus (HCV) 5' Untranslated Region in HIV/HCV Coinfected Patients Treated with Pegylated Interferon and Ribavirin.
Bukowska-Ośko I; Pawełczyk A; Perlejewski K; Kubisa N; Caraballo Cortés K; Rosińska M; Płoski R; Fic M; Kaźmierczak J; Popiel M; Ząbek P; Horban A; Radkowski M; Laskus T
PLoS One; 2015; 10(5):e0125604. PubMed ID: 25932941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
